Form D · Biotechnology

Tangen Biosciences, Inc.

Branford, CT · CIK 0001661955

Offering snapshot reported Jun 6, 2023 · SEC filing

Reported sold
$465K
Offering amount: $2.5M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 26, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 6, 2023Initial$464,767No comparison9SEC filing
Jul 1, 2020Initial$11,239,731No comparison39SEC filing
Mar 22, 2019Initial$6,689,846No comparison29SEC filing
Nov 2, 2016InitialYet to sellNo comparison0SEC filing
Dec 28, 2015Initial$2,030,403No comparison8SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-483452

Source: Form D, filed Jun 6, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Christopher Benoit Director
Richard C. Birkmeyer, Ph D Director, Executive
Brian Chirico Executive
John Davidson Director, Executive
Vance V. Kershner Director
Alan Levin Director
Christopher Mc Leod Director
John Nobile Director
Daniel Wagner Director
Dan Wagner Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
20 Commercial Street
Branford, CT, 06405